Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2017 Filed Jul 18, 2017 15:23 UTC |
HUBBARD ROBERT GLENNDirector
|
GrantPerformance Rights · Derivative | 138.83 | $37.19 | $5,163.09 |
DisclosureSEC source: 0001209191-17-045440 · doc4.xml · derivative · entry 1 HUBBARD ROBERT GLENN · CIK 0001283051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,058 Underlying: Common Stock · 138.83 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 15:20 UTC |
Harris Jerrold BDirector
|
GrantPerformance Rights · Derivative | 149.94 | $37.19 | $5,576.27 |
DisclosureSEC source: 0001209191-17-045432 · doc4.xml · derivative · entry 1 Harris Jerrold B · CIK 0001333739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,183.59 Underlying: Common Stock · 149.94 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| April 13, 2017 Filed Apr 17, 2017 17:48 UTC |
CAVANAGH RICHARDDirector
|
GrantPerformance Rights · Derivative | 99.64 | $34.21 | $3,408.68 |
DisclosureSEC source: 0001209191-17-027107 · doc4.xml · derivative · entry 1 CAVANAGH RICHARD · CIK 0001075522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 911.92 Underlying: Common Stock · 99.64 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| April 13, 2017 Filed Apr 17, 2017 22:32 UTC |
KESTER W CARLDirector
|
GrantPerformance Rights · Derivative | 38.65 | $34.21 | $1,322.22 |
DisclosureSEC source: 0001209191-17-027152 · doc4.xml · derivative · entry 1 KESTER W CARL · CIK 0001141904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,016.45 Underlying: Common Stock · 38.65 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| April 13, 2017 Filed Apr 17, 2017 18:36 UTC |
ROBARDS KAREN PDirector
|
GrantPerformance Rights · Derivative | 40.1 | $34.21 | $1,371.82 |
DisclosureSEC source: 0001209191-17-027156 · doc4.xml · derivative · entry 1 ROBARDS KAREN P · CIK 0001141903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420.69 Underlying: Common Stock · 40.1 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| April 13, 2017 Filed Apr 17, 2017 18:18 UTC |
Lynch Catherine A.Director
|
GrantPerformance Rights · Derivative | 59.91 | $34.21 | $2,049.52 |
DisclosureSEC source: 0001209191-17-027128 · doc4.xml · derivative · entry 1 Lynch Catherine A. · CIK 0001668396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121.53 Underlying: Common Stock · 59.91 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| April 13, 2017 Filed Apr 17, 2017 17:37 UTC |
Castellano Michael JDirector
|
GrantPerformance Rights · Derivative | 89.86 | $34.21 | $3,074.11 |
DisclosureSEC source: 0001209191-17-027099 · doc4.xml · derivative · entry 1 Castellano Michael J · CIK 0001326138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151.86 Underlying: Common Stock · 89.86 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| April 13, 2017 Filed Apr 17, 2017 22:24 UTC |
HUBBARD ROBERT GLENNDirector
|
GrantPerformance Rights · Derivative | 150.97 | $34.21 | $5,164.68 |
DisclosureSEC source: 0001209191-17-027142 · doc4.xml · derivative · entry 1 HUBBARD ROBERT GLENN · CIK 0001283051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,886.27 Underlying: Common Stock · 150.97 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| April 13, 2017 Filed Apr 17, 2017 21:59 UTC |
Harris Jerrold BDirector
|
GrantPerformance Rights · Derivative | 163.05 | $34.21 | $5,577.94 |
DisclosureSEC source: 0001209191-17-027115 · doc4.xml · derivative · entry 1 Harris Jerrold B · CIK 0001333739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,998.79 Underlying: Common Stock · 163.05 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| January 31, 2017 Filed Mar 27, 2017 16:15 UTC |
Xie H ErinPortfolio Manager
|
GrantPhantom Shares · Derivative | 4,062.12 | $33.12 | $134,537.41 |
DisclosureSEC source: 0001209191-17-022912 · doc4.xml · derivative · entry 1 Xie H Erin · CIK 0001320932 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,062.12 Underlying: Common Stock · 4,062.12 shares Expires not disclosed F1 · derivative.exercise_price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. These phantom shares vest in equal installments on each of the first three anniversaries of the award. F1 · derivative.exercise_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. These phantom shares vest in equal installments on each of the first three anniversaries of the award. F1 · derivative.expiration_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. These phantom shares vest in equal installments on each of the first three anniversaries of the award. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 10:42 UTC |
CAVANAGH RICHARDDirector
|
GrantPerformance Rights · Derivative | 101.3 | $33.65 | $3,408.75 |
DisclosureSEC source: 0001209191-17-004016 · doc4.xml · derivative · entry 1 CAVANAGH RICHARD · CIK 0001075522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 798.37 Underlying: Common Stock · 101.3 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 15:55 UTC |
KESTER W CARLDirector
|
GrantPerformance Rights · Derivative | 39.29 | $33.65 | $1,322.11 |
DisclosureSEC source: 0001209191-17-004045 · doc4.xml · derivative · entry 1 KESTER W CARL · CIK 0001141904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 960.55 Underlying: Common Stock · 39.29 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 11:06 UTC |
ROBARDS KAREN PDirector
|
GrantPerformance Rights · Derivative | 40.76 | $33.65 | $1,371.57 |
DisclosureSEC source: 0001209191-17-004067 · doc4.xml · derivative · entry 1 ROBARDS KAREN P · CIK 0001141903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374.03 Underlying: Common Stock · 40.76 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 10:57 UTC |
Lynch Catherine A.Director
|
GrantPerformance Rights · Derivative | 60.9 | $33.65 | $2,049.29 |
DisclosureSEC source: 0001209191-17-004056 · doc4.xml · derivative · entry 1 Lynch Catherine A. · CIK 0001668396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60.9 Underlying: Common Stock · 60.9 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 10:38 UTC |
Castellano Michael JDirector
|
GrantPerformance Rights · Derivative | 91.35 | $33.65 | $3,073.93 |
DisclosureSEC source: 0001209191-17-004007 · doc4.xml · derivative · entry 1 Castellano Michael J · CIK 0001326138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043.56 Underlying: Common Stock · 91.35 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 15:52 UTC |
HUBBARD ROBERT GLENNDirector
|
GrantPerformance Rights · Derivative | 153.48 | $33.65 | $5,164.60 |
DisclosureSEC source: 0001209191-17-004036 · doc4.xml · derivative · entry 1 HUBBARD ROBERT GLENN · CIK 0001283051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,705.19 Underlying: Common Stock · 153.48 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 15:46 UTC |
Harris Jerrold BDirector
|
GrantPerformance Rights · Derivative | 165.76 | $33.65 | $5,577.82 |
DisclosureSEC source: 0001209191-17-004027 · doc4.xml · derivative · entry 1 Harris Jerrold B · CIK 0001333739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,803.91 Underlying: Common Stock · 165.76 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 13:02 UTC |
CAVANAGH RICHARDDirector
|
GrantPerformance Rights · Derivative | 40.71 | $33.43 | $1,360.94 |
DisclosureSEC source: 0001209191-16-146154 · doc4.xml · derivative · entry 1 CAVANAGH RICHARD · CIK 0001075522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671.54 Underlying: Common Stock · 40.71 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 17:12 UTC |
KESTER W CARLDirector
|
GrantPerformance Rights · Derivative | 90.8 | $33.43 | $3,035.44 |
DisclosureSEC source: 0001209191-16-146180 · doc4.xml · derivative · entry 1 KESTER W CARL · CIK 0001141904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887.75 Underlying: Common Stock · 90.8 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 13:15 UTC |
ROBARDS KAREN PDirector
|
GrantPerformance Rights · Derivative | 20.48 | $33.43 | $684.65 |
DisclosureSEC source: 0001209191-16-146188 · doc4.xml · derivative · entry 1 ROBARDS KAREN P · CIK 0001141903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321.07 Underlying: Common Stock · 20.48 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 12:59 UTC |
Castellano Michael JDirector
|
GrantPerformance Rights · Derivative | 91.79 | $33.43 | $3,068.54 |
DisclosureSEC source: 0001209191-16-146146 · doc4.xml · derivative · entry 1 Castellano Michael J · CIK 0001326138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 917.56 Underlying: Common Stock · 91.79 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 17:09 UTC |
HUBBARD ROBERT GLENNDirector
|
GrantPerformance Rights · Derivative | 154.22 | $33.43 | $5,155.57 |
DisclosureSEC source: 0001209191-16-146170 · doc4.xml · derivative · entry 1 HUBBARD ROBERT GLENN · CIK 0001283051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,495.28 Underlying: Common Stock · 154.22 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 17:05 UTC |
Harris Jerrold BDirector
|
GrantPerformance Rights · Derivative | 166.55 | $33.43 | $5,567.77 |
DisclosureSEC source: 0001209191-16-146162 · doc4.xml · derivative · entry 1 Harris Jerrold B · CIK 0001333739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,578.6 Underlying: Common Stock · 166.55 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.